Qianming Xu, Ellie D Wilson, Mai Hamasaki, Hirobumi Suzuki, Ayumi Tanaka, Junko Okuda-Shimazaki, Miho Oda, Daimei Miura, Koji Sode, Ryutaro Asano
{"title":"Engineering of pH-regenerable anti-insulin single chain variable fragments (scFvs) for continuous insulin monitoring.","authors":"Qianming Xu, Ellie D Wilson, Mai Hamasaki, Hirobumi Suzuki, Ayumi Tanaka, Junko Okuda-Shimazaki, Miho Oda, Daimei Miura, Koji Sode, Ryutaro Asano","doi":"10.1093/jb/mvag071","DOIUrl":null,"url":null,"abstract":"<p><p>To realize the continuous monitoring of insulin, the development of a regenerable engineered antibody is expected, whose binding constant is modulated by the mild in situ stimulation for future in vivo application. In this study, we aimed to develop pH-responsive anti-insulin antibodies based on a clinically established analytical antibody, the HUI-018 anti-insulin antibody. Its high-resolution co-crystal structure with human insulin (PDB ID: 6Z7W) provides a uniquely precise blueprint for molecular engineering by preparing engineered HUI-018 single-chain variable fragment (scFv). Among the engineered variants, the N93H/E101K mutant exhibited the biggest pH-responsiveness, showing a 5.2-folds increased dissociation rate at pH 6.0 while maintaining binding affinity and specificity comparable to wild-type (WT) at pH 7.4. Repeated cycles of insulin binding at pH 7.4 and regeneration at pH 6.0 demonstrated that the N93H/E101K mutant achieved substantially higher regeneration and rebinding efficiencies than WT. These results demonstrate that engineered pH-responsive antibody enables efficient binding site regeneration through mild pH change. To our knowledge, this is the first report of an anti-insulin antibody capable of binding site regeneration at pH 6.0, representing an important step toward antibody-based continuous insulin monitoring and continuous sensing of protein biomarkers.</p>","PeriodicalId":15234,"journal":{"name":"Journal of biochemistry","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biochemistry","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1093/jb/mvag071","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
To realize the continuous monitoring of insulin, the development of a regenerable engineered antibody is expected, whose binding constant is modulated by the mild in situ stimulation for future in vivo application. In this study, we aimed to develop pH-responsive anti-insulin antibodies based on a clinically established analytical antibody, the HUI-018 anti-insulin antibody. Its high-resolution co-crystal structure with human insulin (PDB ID: 6Z7W) provides a uniquely precise blueprint for molecular engineering by preparing engineered HUI-018 single-chain variable fragment (scFv). Among the engineered variants, the N93H/E101K mutant exhibited the biggest pH-responsiveness, showing a 5.2-folds increased dissociation rate at pH 6.0 while maintaining binding affinity and specificity comparable to wild-type (WT) at pH 7.4. Repeated cycles of insulin binding at pH 7.4 and regeneration at pH 6.0 demonstrated that the N93H/E101K mutant achieved substantially higher regeneration and rebinding efficiencies than WT. These results demonstrate that engineered pH-responsive antibody enables efficient binding site regeneration through mild pH change. To our knowledge, this is the first report of an anti-insulin antibody capable of binding site regeneration at pH 6.0, representing an important step toward antibody-based continuous insulin monitoring and continuous sensing of protein biomarkers.
期刊介绍:
The Journal of Biochemistry founded in 1922 publishes the results of original research in the fields of Biochemistry, Molecular Biology, Cell, and Biotechnology written in English in the form of Regular Papers or Rapid Communications. A Rapid Communication is not a preliminary note, but it is, though brief, a complete and final publication. The materials described in Rapid Communications should not be included in a later paper. The Journal also publishes short reviews (JB Review) and papers solicited by the Editorial Board.